Synovial sarcoma X breakpoint 2 (SSX2)

Synovial sarcoma X breakpoint 2 (SSX2) is a member of the SSX gene family classified as a cancer/testis antigen, with normal mRNA and protein expression highly restricted to testis germline cells. It functions as a putative transcriptional repressor and chromatin-associated protein, influencing gene expression and cell identity. SSX2 is best known for participating in oncogenic SS18-SSX2 fusion proteins characteristic of synovial sarcoma, contributing to tumorigenesis via aberrant epigenetic and transcriptomic reprogramming. Beyond synovial sarcoma, SSX2 is aberrantly expressed in a range of cancers, including melanoma, breast, prostate, colorectal, and liver cancers—there, it promotes cell proliferation, migration, invasiveness, and may induce DNA damage and genomic instability. SSX2 is highly immunogenic, eliciting humoral and cellular immune responses in patients, making it an attractive target for cancer immunotherapy (e.g., peptide vaccines). However, it is heterogeneously expressed in tumors, which could enable immune escape, and therapeutic strategies may need to address the risks of targeting an antigen with exclusive germline expression in normal tissues.

Other names

Protein SSX2SSX2ACT5.2HOM-MEL-40HD21MGC3884MGC15364MGC119055CT5.2aCancer/testis antigen 5.2Tumor antigen HOM-MEL-40Cancer/testis antigen family 5 member 2Synovial sarcoma, X breakpoint 2Bsynovial sarcoma, X-chromosome-related 2

T cell recognition and cytotoxicity to SSX2-derived epitopes (e.g., HLA-A2–restricted peptides); Induction of antibody immune responses via vaccination or spontaneous immunity in cancer; Upregulation of SSX2 via epigenetic modulation (e.g., DNA demethylating agents)